VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2021 | How does eptinezumab differ from other migraine treatments?

Eptinezumab is a calcitonin gene-related peptide (CGRP)-targeting monoclonal antibody approved for the preventive treatment of chronic and episodic migraine. Roger Cady, MD, Lundbeck Pharmaceutical, discusses the unique aspects of eptinezumab as the first intravenous (IV) migraine prophylactic. The IV formulation confers a very rapid onset of activity, with trial evidence demonstrating efficacy from the day after infusion that is sustained for up to three months. Eptinezumab is well tolerated and highly efficacious, with around 50% of patients experiencing ≥50% reduction in monthly migraine days. This interview took place during the European Academy of Neurology 2021 congress.